Crescent Biopharma, Inc. (CBIO) earnings
Quarterly results of Crescent Biopharma, Inc. as filed with the SEC: revenue, net income and earnings per share for each of the last 8 quarters, the latest results release and when the next one is expected.
Next earnings date
Crescent Biopharma, Inc. was expected to report around November 5, 2026; nothing is on file with the SEC yet.
Latest quarter: Q2 FY2026
In Q2 FY2026 (ended June 30, 2026) Crescent Biopharma, Inc. reported revenue of $0 and a net loss of $24.8M.
Quarter by quarter
| Quarter | Revenue | vs year ago | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | $0 | - | -$24.8M | - |
| Q1 FY2026 | $1M | - | -$23.3M | - |
| Q4 FY2025 | - | - | -$23.3M | - |
| Q3 FY2025 | - | - | -$24.6M | - |
| Q2 FY2025 | $0 | - | -$21.8M | - |
| Q1 FY2025 | $0 | - | -$15.1M | -$0.04 |
| Q4 FY2024 | - | - | -$7.2M | - |
| Q3 FY2024 | - | - | -$9.8M | -$0.15 |
Results filings
- Quarterly report 10-Q
- Quarterly results 8-K
- Quarterly results 8-K
- Quarterly report (amended) 10-Q/A
- Quarterly results 8-K
- Quarterly report 10-Q
When is Crescent Biopharma, Inc.'s next earnings date?
Crescent Biopharma, Inc. was expected to report around November 5, 2026; nothing is on file with the SEC yet.
What were Crescent Biopharma, Inc.'s latest quarterly results?
For Q2 FY2026, which ended June 30, 2026, Crescent Biopharma, Inc. reported revenue of $0 and a net loss of $24.8M. The figures come from its filing with the SEC.
Get an email when CBIO reports
Follow CBIO and we email you its next results the day they are filed, with the numbers explained.